l-Phenylalanine Triflate as Organocatalyst for Divergent ­Approaches to Trisubstituted Hexahydroimidazo[1,2-a]pyridine and 1,4-Diazepane Derivatives

Jun Jiang; Miao Zhang; Wen-Biao Wu; Hai-Bo Lu; Yu-Long Shi; Jian-Jun Li

doi:10.1055/s-0036-1589115

Synlett, Inhaltsverzeichnis

Synlett 2018; 29(02): 246-250
DOI: 10.1055/s-0036-1589115

letter

l-Phenylalanine Triflate as Organocatalyst for Divergent Approaches to Trisubstituted Hexahydroimidazo[1,2-a]pyridine and 1,4-Diazepane Derivatives

Autor*innen

Jun Jiang

^aNational Engineering Research Center for Process Development of Active Pharmaceutical Ingredients, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. of China eMail: lijianjun@zjut.edu.cn

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China
Miao Zhang

^aNational Engineering Research Center for Process Development of Active Pharmaceutical Ingredients, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. of China eMail: lijianjun@zjut.edu.cn
Wen-Biao Wu

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China
Hai-Bo Lu

^aNational Engineering Research Center for Process Development of Active Pharmaceutical Ingredients, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. of China eMail: lijianjun@zjut.edu.cn

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China
Yu-Long Shi

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China
Jian-Jun Li*

^aNational Engineering Research Center for Process Development of Active Pharmaceutical Ingredients, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, P. R. of China eMail: lijianjun@zjut.edu.cn

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. of China

Abstract

Alle Artikel dieser Rubrik

Abstract

The convergent synthesis of two biologically significant classes of trisubstituted hexahydroimidazo[1,2-a]pyridine and 1,4-diazepane derivatives from readily available aromatic aldehydes, ketones, and ethane-1,2-diamine is reported. This protocol is promoted by the highly effective l-phenylalanine triflate catalyst through intermolecular annulation, and tolerates a variety of functional groups with excellent yields.

Key words

multicomponent reactions - nitrogen heterocycles - imidazopyridines - diazepanes - organocatalysis - phenylalanine triflate

Volltext

Referenzen

References and Notes

1a Deiters A. Martin SF. Chem. Rev. 2004; 104: 2199
1b Zhao W. Chem. Rev. 2010; 110: 1706

2a Cheng D. Croft L. Abdi M. Lightfoot A. Gallagher T. Org. Lett. 2007; 9: 5175
2b Andrews MD. af Forselles K. Beaumont K. Galan SR. Glossop PA. Grenie M. Jessiman A. Kenyon AS. Lunn G. Maw G. Owen RM. Pryde DC. Roberts D. Tran TD. ACS Med. Chem. Lett. 2015; 6: 419
2c Enguehard-Gueiffier CE. Fauvelle F. Debouzy JC. Peinnequin A. Thery I. Dabouis V. Gueiffier A. Eur. J. Pharm. Sci. 2005; 24: 219
2d Hamdouchi C. de Blas J. del Prado M. Gruber J. Heinz BA. Vance L. J. Med. Chem. 1999; 42: 50
2e Srivastava P. Pandey VC. Misra AP. Gupta P. Raj K. Bhaduri AP. Bioorg. Med. Chem. 1998; 6: 181
2f Badawey E. Kappe T. Eur. J. Med. Chem. 1995; 30: 327
2g Kaminski JJ. Doweyko AM. J. Med. Chem. 1997; 40: 427
2h Gueiffier A. Mavel S. Lhassani M. Elhakmaoui A. Snoeck R. Andrei G. Chavignon O. Teulade J.-C. Witvrouw M. Balzarini J. De Clercq E. Chapat JP. J. Med. Chem. 1998; 41: 5108

3 Okubo T. Yoshikawa R. Chaki S. Okuyama S. Nakazato A. Bioorg. Med. Chem. 2004; 12: 423
4 Almirante L. Polo L. Mugnaini A. Provinciali E. Rugarli P. Biancotti A. Gamba A. Murmann W. J. Med. Chem. 1965; 8: 305

5a Katritzky AR. Xu Y.-J. Tu H. J. Org. Chem. 2003; 68: 4935
5b Hanson SM. Morlock EV. Satyshur KA. Czajkowski C. J. Med. Chem. 2008; 51: 7243

6 Kukla MJ. Breslin HJ. J. Org. Chem. 1987; 52: 5046
7 Márton-Merész M. Zára-Kaczián E. Boros S. Mátyus P. J. Heterocycl. Chem. 1997; 34: 1033

8a Santra S. Bagdi AK. Majee A. Hajra A. Adv. Synth. Catal. 2013; 355: 1065
8b Monir K. Bagdi AK. Ghosh M. Hajra A. Org. Lett. 2014; 16: 4630

9a Bagdi AK. Rahman M. Santra S. Majee A. Hajra A. Adv. Synth. Catal. 2013; 355: 1741
9b Mohan DC. Donthiri RR. Rao SN. Adimurthy S. Adv. Synth. Catal. 2013; 355: 2217
9c Cai Z.-J. Wang S.-Y. Ji S.-J. Adv. Synth. Catal. 2013; 355: 2686

10 Wang R.-L. Zhu P. Lu Y. Huang F.-P. Hui X.-P. Adv. Synth. Catal. 2013; 355: 87

11a Li J. Lu L. Su W. Tetrahedron Lett. 2010; 51: 2434
11b Ramalingan C. Park S.-J. Lee I.-S. Kwak Y.-W. Tetrahedron 2010; 66: 2987

12 Li J. He P. Yu C. Tetrahedron 2012; 68: 4138
13 Trisubstituted hexahydroimidazo[1,2-a] pyridines 4a–r; General ProcedureThe appropriate aldehyde (1.0 mmol), ketone (2.5 mmol), H₂N(CH₂)₂NH₂ (1.0 mmol), and MeOH (5.0 mL) were mixed with LPAT (10 mol%), and the mixture was refluxed for 24 h. The solvent was evaporated and the residue was crystallized.5,7,8a-Triphenyl-1,2,3,7,8,8a-hexahydroimidazo[1,2-a]pyridine (4a)White solid; yield: 320.5 mg (91%); mp 133.5–134.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.68–7.61 (m, 4 H), 7.39–7.16 (m, 11 H), 4.97 (s, 1 H), 3.62–3.56 (m, 1 H), 3.18–3.05 (m, 2 H), 3.00–2.94 (m, 2 H), 2.45 (dd, J = 12.4, 5.6 Hz, 1 H), 2.17 (s, 1 H), 1.87 (t, J = 12.4 Hz, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ = 145.7, 145.4, 144.9, 139.7, 128.4, 128.3, 127.9, 127.4, 127.2, 126.2, 125.9, 107.5, 80.8, 52.5, 44.4, 41.8, 39.4. MS (ESI): m/z = 353.2 [M + 1]⁺.7-(3,4-Dimethylphenyl)-5,8a-diphenyl-1,2,3,7,8,8a-hexahydroimidazo[1,2-a]pyridine (4c)Pale-yellow solid; yield: 353.6 mg (93%); mp 122.8–123.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.64 (dd, J = 16.0, 7.2 Hz, 4 H), 7.38–7.27 (m, 6 H), 7.05–6.96 (m, 3 H), 4.96 (s, 1 H), 3.61–3.55 (m, 1 H), 3.17–3.04 (m, 2 H), 3.00–2.89 (m, 2 H), 2.42 (dd, J = 12.0, 5.6 Hz, 1 H), 2.24 (s, 3 H), 2.23 (s, 3 H), 2.13 (s, 1 H), 1.86 (t, J = 12.4 Hz, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ = 145.4, 145.0, 142.8, 139.7, 136.5, 134.4, 129.7, 128.8, 128.4, 128.2, 127.8, 127.4, 127.2, 126.0, 124.8, 108.1, 80.8, 52.5, 44.4, 41.7, 39.0, 20.1, 19.6. MS (ESI): m/z = 381.2 [M + 1]⁺. HRMS-ESI: m/z calcd for C₂₇H₂₉N₂: 381.2325; found: 381.2345.
14 Fujioka H. Murai K. Kubo O. Ohba Y. Kita Y. Org. Lett. 2007; 9: 1687

15a Murai K. Nakatani R. Kita Y. Fujioka H. Tetrahedron 2008; 64: 11034
15b Sotoca E. Allais C. Constantieux T. Rodriguez J. Org. Biomol. Chem. 2009; 7: 1911
15c Lal M. Basha RS. Sarkar S. Khan AT. Tetrahedron Lett. 2013; 54: 4264

16 1,4-Diazepane 6a–h; General Procedure Aromatic aldehyde (1.0 mmol), ethyl acetoacetate (1.2 mmol), H₂N(CH₂)₂NH₂ (1.0 mmol), and toluene (5.0 mL) were mixed with LPAT (10 mol%), and the mixture was refluxed for 24 h. The solvent was evaporated under reduced pressure to afford the crude compound, which was purified by flash chromatography (silica gel).Ethyl (2Z)-(7-Phenyl-1,4-diazepan-5-ylidene)acetate (6a)Yellow oil; yield: 161.2 mg (62%). ¹H NMR (400 MHz, CDCl₃): δ = 8.90 (br s, 1 H), 7.35–7.24 (m, 5 H), 4.45 (s, 1 H), 4.09 (q, J = 7.2 Hz, 2 H), 3.75 (d, J = 10.0 Hz, 1 H), 3.62–3.55 (m, 1 H), 3.42–3.35 (m, 1 H), 3.16 (dd, J = 12.8, 4.4 Hz, 1 H), 2.98–2.82 (m, 2 H), 2.34 (d, J = 14.4 Hz, 1 H), 1.93 (br s, 1 H), 1.25 (t, J = 7.2 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 170.6, 165.4, 145.0, 128.8, 127.7, 126.4, 82.5, 62.8, 58.7, 51.0, 46.5, 46.2, 14.9. MS (ESI): m/z = 261.0 [M + 1]⁺.
17 CCDC 1422263 contains the supplementary crystallographic data for compound 4a. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.

Zusatzmaterial

l-Phenylalanine Triflate as Organocatalyst for Divergent ­Approaches to Trisubstituted Hexahydroimidazo[1,2-a]pyridine and 1,4-Diazepane Derivatives

Autor*innen

l-Phenylalanine Triflate as Organocatalyst for Divergent Approaches to Trisubstituted Hexahydroimidazo[1,2-a]pyridine and 1,4-Diazepane Derivatives